

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
18 August 2005 (18.08.2005)

PCT

(10) International Publication Number  
WO 2005/075449 A1

(51) International Patent Classification<sup>7</sup>: C07D 311/32, A61K 31/352

(74) Agent: COLEMAN, Henry, D.; Coleman Sudol Sapone, P.C., 714 Colorado Avenue, Bridgeport, CT 06605-1601 (US).

(21) International Application Number:  
PCT/US2005/002910

(22) International Filing Date: 31 January 2005 (31.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/541,443 3 February 2004 (03.02.2004) US

(71) Applicant (for all designated States except US): YALE UNIVERSITY [US/US]; Two Whitney Avenue, New Haven, CT 06511 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHENG, Yung-Chi [US/US]; 961 Baldwin Rd., New Haven, CT 06525 (US). LEE, Yashang [CN/US]; 470 Prospect St., Apt. 31, New Haven, CT 06511 (US). YEO, Hosup [KR/KR]; Cheil Apt. B-303, 246-3 Shinam-4-dong, Dong-ku, Daegu 701-816 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: COMPOUNDS AND METHODS TO INCREASE ANTI-P-GLYCOPROTEIN ACTIVITY OF BAICALEIN BY ALKYLATION ON THE A RING

Table 3. Anti-P-gp activity and cytotoxicity of alkylated baicalein compounds.

compd	functional group				c log P <sup>a</sup>	anti-P-gp activity <sup>a</sup>		cytotoxicity (C <sub>50</sub> μM)	
	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	R <sup>8</sup>		EC <sub>50</sub> (μM) <sup>a</sup>	Δ <sub>max</sub> <sup>a</sup>	KB	KD/MDR
control							0.5±0.1 <sup>1</sup>		
CSA					2.9	1.2±0.3	3.5±0.3	0.6±0.2	1.5±0.7
VRM					4.5	14±1.2	2.2±0.1	19.6±2.7	51.7±4.7
1	OH	OH	OH	H	3.0	41±5.1	1.7±0.1	62.3±3.7	87.1±3.6
8	OH	OMe	OMe	H	3.5	4.6±1.1	3.4±0.3	>100	>100
6	OMe	OMe	OMe	H	2.9	5.5±0.4	2.7±0.2	83.9±7.8	57.9±5.9
19	OH	OCH <sub>3</sub> O		H	3.7	6.5±1.3	1.2±0.1	>100	>100
20	OMe	OCH <sub>3</sub> O		H	3.1	4.4±2.1	1.5±0.1	>100	>100
32	OH	OEt	OH	H	3.6	2.3±0.3	3.5±0.3	24.6±3.5	17.5±5.6
38	OH	OEt	OMe	H	4.1	1.5±0.3	2.3±0.2	>100	>100
33	OH	OEt	OEt	H	4.6	1.8±0.2	4.9±0.2	>100	>100
44	OMe	OEt	OEt	H	3.9	1.1±0.1	4.2±1.1	81.7±7.8	79.2±5.8
17	OH	OPr	OH	H	4.1	2±0.7	4.7±0.1	58.9±6.3	>100
21	OH	OPr	OMe	H	4.6	1.2±0.4	4.6±0.1	>100	>100
22	OMe	OPr	OMe	H	3.9	1.7±0.1	4.6±0.1	>100	>100
18	OH	OPr	OPr	H	5.6	1.4±0.4	5.0±0.2	>100	>100
23	OMe	OPr	OPr	H	5.0	0.9±0.1	5.2±0.1	86.4±6.3	93.7±2.2
45	OH	OC <sub>2</sub> H <sub>5</sub>	OC <sub>2</sub> H <sub>5</sub>	H	6.7	1.5±0.3	3.2±0.1	>100	>100
46	OMe	OC <sub>2</sub> H <sub>5</sub>	OC <sub>2</sub> H <sub>5</sub>	H	6.1	1.6±0.2	4.4±0.1	>100	>100
40	OH	OC <sub>3</sub> H <sub>7</sub>	OC <sub>3</sub> H <sub>7</sub>	H	7.8	1.8±0.1	1.1±0.1	>100	>100
41	OMe	OC <sub>3</sub> H <sub>7</sub>	OC <sub>3</sub> H <sub>7</sub>	H	7.1	1.5±0.1	3.2±0.1	75.4±6.4	82.6±8.4
42	OH	OC <sub>4</sub> H <sub>9</sub>	OC <sub>4</sub> H <sub>9</sub>	H	8.8	1±0.1	1.0±0.1	>100	>100
43	OMe	OC <sub>4</sub> H <sub>9</sub>	OC <sub>4</sub> H <sub>9</sub>	H	8.2	1.3±0.2	1.1±0.1	39.1±8.5	44.8±7.9
34	OH	OC <sub>6</sub> H <sub>13</sub>	OC <sub>6</sub> H <sub>13</sub>	H	10.9	7.4±4.1	1.2±0.1	>100	>100

Me = methyl, Et = ethyl, Pr = n-propyl and Ph = phenyl.

(57) Abstract: The present invention is directed to analogs of baicalein according to formula (I): where R<sup>5</sup> is H, (C<sub>1</sub>-C<sub>12</sub>)alkyl, (C<sub>2</sub>-C<sub>13</sub>)acyl, or an optionally substituted phenyl or benzyl group, an acyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl or ether group, a phosphate, diphosphate, triphosphate or phosphodiester group; R<sup>6</sup> and R<sup>7</sup> are each independently H, (C<sub>1</sub>-C<sub>12</sub>)alkyl, (C<sub>2</sub>-C<sub>13</sub>)acyl, or an optionally substituted phenyl or benzyl or together form a -OCR<sup>1</sup>R<sup>2</sup>O- group wherein each of R<sup>1</sup> and R<sup>2</sup> is independently H, a C<sub>1</sub>-C<sub>3</sub> alkyl group or an optionally substituted phenyl or benzyl group; and R<sup>8</sup> is H, OH, an O-acyl group, a C<sub>1</sub>-C<sub>4</sub> alkyl or alkoxy group, F, Cl, Br or I, or a pharmaceutically acceptable salt thereof, which exhibit anti-P-glycoprotein activity and methods of enhancing the bioavailability of active compounds, especially orally administered compounds, by inhibition of P-glycoprotein 170 (P-gp 170) and/or CYP450 enzyme, especially CYP450 3A4 enzyme. Pharmaceutical compositions based upon these novel derivatives according to the present invention are also described herein.



**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*